Your institution may have access to this item. Find your institution then sign in to continue.

Title: Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Authors: Stathis, Anastasios; Tolcher, Anthony W.; Wang, Judy S.; Renouf, Daniel J.; Chen, Lin-Chi; Suttner, Leah H.; Freshwater, Tomoko; Webber, Andrea L.; Nayak, Tapan; Siu, Lillian L.
Publication: Investigational New Drugs, 2023, Vol 41, Issue 3, p380
ISSN: 0167-6997
Publication type: Academic Journal
DOI: 10.1007/s10637-022-01326-3

We found a match

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.